Research Compound
CJC-1295 (no DAC)
CJC-1295 (no DAC), also known as Mod GRF 1-29, is a synthetic 29-amino acid GHRH analog, available as a lyophilized powder for laboratory research.
Select Size
10mg
SKU: CND10
Batch: 202601-01-CND
$49.99
Ships today if ordered by 4PM EST
Est. Arrival: 09/18/2026
Volume Discounts
Qty: 1 - 4$49.99 each
Qty: 5 - 9$44.99 each(save $5.00)
Qty: 10+$39.99 each(save $10.00)
Quantity:
1
For Research Use Only. This product is intended for laboratory and scientific research purposes only. It is not a drug or dietary supplement and is not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease.
99%+ Purity
COA Included
Fast Shipping
USA Based
Product Details
CJC-1295 (no DAC) (Modified GRF 1-29) is a synthetic 29-amino acid tetrasubstituted GHRH analog. Contains four substitutions vs native GHRH: D-Ala2, Ala8, Leu15, Leu27 for increased DPP-4 resistance.
Unlike CJC-1295 with DAC, does not contain Drug Affinity Complex and does not exhibit albumin binding. Soluble in sterile water or bacteriostatic water. Store at -20°C.
Disclaimer: For laboratory and research purposes only. Not intended for human consumption.
Frequently Asked Questions About CJC-1295 (no DAC)
Answers summarize published research and are provided for laboratory research purposes only.
CJC-1295 (no DAC), also called Modified GRF 1-29 or Mod GRF 1-29, is a synthetic 29 amino acid analog of growth hormone releasing hormone, or GHRH. It carries four substitutions compared with native GHRH: D-Ala2, Ala8, Leu15, and Leu27. Research studies have examined CJC-1295 (no DAC) as a GHRH analog with improved resistance to enzymatic breakdown. Biotech Compounds supplies it as a lyophilized powder for laboratory research.
In research studies, CJC-1295 (no DAC) has been observed to act at the GHRH receptor on pituitary cells, where it mimics the signal of native GHRH. Researchers reported that the four amino acid substitutions increase resistance to the enzyme DPP-4, which rapidly degrades native GHRH. Published research describes CJC-1295 (no DAC) as a short acting GHRH analog that produces a pulse like signal in experimental systems.
The primary research area for CJC-1295 (no DAC) is growth hormone axis research. In animal models and in vitro pituitary cell studies, researchers reported that CJC-1295 (no DAC) stimulated growth hormone release in a pulsatile pattern that resembled the natural rhythm. It is often used in research protocols that examine GHRH receptor signaling and the regulation of growth hormone secretion.
Ipamorelin is a growth hormone secretagogue that acts at the ghrelin receptor, while CJC-1295 (no DAC) acts at the GHRH receptor. Research studies have reported that stimulating the two receptor pathways together produced additive effects on growth hormone release in experimental models. Biotech Compounds also offers an Ipamorelin/CJC-1295 (no DAC) 5MG/5MG blend for researchers who study the two compounds in combination.
Modified GRF 1-29 has been studied in animal models, in vitro pituitary cell systems, and early human pharmacology research examining GHRH analogs. CJC-1295 (no DAC) is not approved by the FDA and has not completed late stage clinical development. Its reported activity on growth hormone release remains investigational, and Biotech Compounds supplies it only for laboratory study.
Both share the same modified GHRH(1-29) sequence with four substitutions. CJC-1295 W/ DAC adds a Drug Affinity Complex that binds covalently to albumin, which research has reported extends its half-life to several days. CJC-1295 (no DAC) has no albumin binding, and researchers reported a half-life measured in minutes. In experimental models the no DAC form produces short pulses while the DAC form produces sustained elevation.
CJC-1295 (no DAC) is supplied as a lyophilized powder and is soluble in sterile water or Bacteriostatic Water. In the laboratory, the diluent is added slowly down the inside wall of the vial, and the vial is swirled gently until the powder dissolves. The vial should never be shaken, since agitation can damage the 29 amino acid chain. Reconstitution volume is set by the experimental design.
Lyophilized CJC-1295 (no DAC) should be stored at -20 C in a dry, dark place. After reconstitution, CJC-1295 (no DAC) should be refrigerated at 2 to 8 C, protected from light, and used within a short window. Repeated freeze thaw cycles should be avoided. Research studies have reported that the no DAC form has a short half-life in biological systems, so timing matters in experimental design.
CJC-1295 (no DAC) from Biotech Compounds is listed at 99 percent plus purity. Each lot is third party tested, and a Certificate of Analysis is available on the CJC-1295 (no DAC) product page so researchers can confirm identity and purity before use. Laboratories are encouraged to review the COA and keep it with their experimental records.
CJC-1295 (no DAC) has the molecular formula C152H252N44O42 and a molecular weight of approximately 3368.7 g/mol. It is a 29 amino acid peptide, which places it among the larger single chain peptides in the catalog. The molecular weight of CJC-1295 (no DAC) is lower than that of CJC-1295 W/ DAC because it lacks the Drug Affinity Complex.
No. CJC-1295 (no DAC) is sold strictly as a research material for laboratory research by qualified researchers and research organizations. Purchasers must be 21 or older. CJC-1295 (no DAC) is not a drug or dietary supplement, and it is not for human or animal consumption. Biotech Compounds supplies it for in vitro and preclinical investigation only.
You May Also Like
